Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors by Nikhil Vojjala et al.
Nikhil Vojjala, MD in Internal Medicine at Trinity Health MI, shared his recent article on X:
Authors: Nikhil Vojjala et al.
Summary:
The article titled “Bosutinib-Induced Pleural Effusion—Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors” presents a case study of a 79-year-old female diagnosed with Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL) in 2015. Initially treated with Imatinib, she was later switched to second-generation tyrosine kinase inhibitors (TKIs).
Over time, she developed recurrent pleural effusions, leading to dyspnea. Despite multiple interventions, including diuretics, thoracentesis, and transitioning through various TKIs, her condition persisted. Notably, even after switching to Bosutinib, a third-generation TKI, the pleural effusions continued.
This case underscores the potential class effect of TKIs in inducing pleural effusions and highlights the challenge of cross-intolerance among different TKIs. Clinicians should be vigilant for such adverse events and consider alternative management strategies when faced with TKI-induced pleural effusions.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023